Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries by Haider, Batool A. & Bhutta, Zulfiqar Ahmed
eCommons@AKU
Woman and Child Health Division of Woman and Child Health
October 2011
Neonatal vitamin A supplementation for the
prevention of mortality and morbidity in term
neonates in developing countries
Batool A. Haider
Aga Khan University, batool.ali@aku.edu
Zulfiqar Ahmed Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_wc
Part of the Maternal and Child Health Commons
Recommended Citation
Haider, B., Bhutta, Z. A. (2011). Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates
in developing countries. Cochrane Database of Systematic Reviews(10), 6980.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/52
Cochrane Database of Systematic Reviews
Neonatal vitamin A supplementation for the prevention of
mortality andmorbidity in term neonates in developing
countries (Review)
Haider BA, Bhutta ZA
Haider BA, Bhutta ZA.
Neonatal vitamin A supplementation for the prevention of mortality andmorbidity in term neonates in developing countries.
Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD006980.
DOI: 10.1002/14651858.CD006980.pub2.
www.cochranelibrary.com
Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
15DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 1 All-cause infant mortality at 6
months: risk ratios based on cumulative risk (%, adjusted for clustering). . . . . . . . . . . . . . 37
Analysis 1.2. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 2 All-cause infant mortality at 6
months: rate ratios (per years of follow-up). . . . . . . . . . . . . . . . . . . . . . . . 38
Analysis 1.3. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 3 All-cause infant mortality at
12 months (all infants): risk ratios based on cumulative risk (%). . . . . . . . . . . . . . . . . 39
Analysis 1.4. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 4 All-cause infant mortality at
12 months: rate ratios (per years of follow-up). . . . . . . . . . . . . . . . . . . . . . . 40
Analysis 1.5. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 5 Cause-specific infant mortality
at 6 months (all infants): Diarrhea. . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Analysis 1.6. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 6 Cause-specific infant mortality
at 6 months (all infants): Respiratory infections. . . . . . . . . . . . . . . . . . . . . . . 41
Analysis 1.7. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 7 Cause-specific infant mortality
at 12 months (all infants): Diarrhoea. . . . . . . . . . . . . . . . . . . . . . . . . . 42
Analysis 1.8. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 8 Cause-speciifc infant mortality
at 12 months (all infants): Respiratory infections. . . . . . . . . . . . . . . . . . . . . . 43
Analysis 1.9. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 9 Infant morbidity at 6 months
(rate ratio): Diarrhoea. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.10. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 10 Infant morbidity at 6
months (rate ratio): Respiratory infections. . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.11. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 11 Vitamin A deficient (serum
retinol <0.70 micromol/L) at 6 weeks of age. . . . . . . . . . . . . . . . . . . . . . . . 45
Analysis 1.12. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 12 Vitamin A deficient (serum
retinol <0.70 micromol/L) at 4 months of age. . . . . . . . . . . . . . . . . . . . . . . 45
Analysis 1.13. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 13 Anaemia (haemoglobin
<105g/L) at 8-14 months of age. . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Analysis 1.14. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 14 Adverse events during the
first 48-72 hours post supplementation. . . . . . . . . . . . . . . . . . . . . . . . . . 46
Analysis 1.15. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 15 Adverse events during the
first month post supplementation. . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
47ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iNeonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
52SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
52INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiNeonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Neonatal vitamin A supplementation for the prevention of
mortality and morbidity in term neonates in developing
countries
Batool A Haider1, Zulfiqar A Bhutta2
1Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA, USA. 2Division of Women and Child
Health, Aga Khan University Hospital, Karachi, Pakistan
Contact address: Zulfiqar A Bhutta, Division of Women and Child Health, Aga Khan University Hospital, Stadium Road, PO Box
3500, Karachi, Sindh, 74800, Pakistan. zulfiqar.bhutta@aku.edu.
Editorial group: Cochrane Neonatal Group.
Publication status and date: New, published in Issue 4, 2012.
Review content assessed as up-to-date: 30 November 2010.
Citation: Haider BA, Bhutta ZA. Neonatal vitamin A supplementation for the prevention of mortality and morbidity in
term neonates in developing countries. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD006980. DOI:
10.1002/14651858.CD006980.pub2.
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Vitamin A deficiency is a major public health problem in developing countries. Vitamin A supplementation in children greater than
six months of age has been found to be beneficial, with no effect of supplementation between one to five months. Supplementation in
the neonatal period has been suggested to have an impact by increasing body stores in early infancy.
Objectives
To evaluate the role of vitamin A supplementation in term neonates in developing countries with respect to the prevention of mortality
and morbidity.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, May 2010), EMBASE and
MEDLINE (1966 to May 2010) via PubMed.
Selection criteria
Randomised and quasi-randomised controlled trials. Trials with factorial designs were also included.
Data collection and analysis
Two review authors independently assessed trial quality and extracted the data.
Main results
Seven trials (51,446 neonates) were included in this review, with only few trials reporting disaggregated data for term infants. Therefore,
we analysed data and presented estimates for term infants (where specified) followed by all infants.
Data for term neonates from three studies showed a statistically significant effect on the risk of infant mortality at six months in the
vitamin A group compared with the control group (typical risk ratio (RR) 0.82; 95% CI 0.68 to 0.99; I2 63%). Analysis of data for all
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infants from five studies showed a 14% reduction in the risk of infant mortality at six months in neonates supplemented with vitamin
A compared to control; this reduction was statistically significant (typical RR 0.86; 95% CI 0.77 to 0.97; I2 39%). These findings
should be interpreted with caution, however, due to the small number of included studies, wide confidence intervals with upper levels
close to the null effect and statistical heterogeneity. Vitamin A supplementation failed to show any significant effect on infant mortality
at 12 months of age compared to control (typical rate ratio 1.03; 95% CI 0.87 to 1.23; I2 49%). Limited data were available for the
outcomes of cause-specific mortality and morbidity, vitamin A deficiency, anaemia and adverse events.
Authors’ conclusions
Considering mortality in early infancy being a major contributory cause of overall child mortality for the under five year old group in
developing countries, it is critical to obtain sound scientific evidence of the effect of vitamin A supplementation in neonates. Evidence
provided in this review does indicate a potential beneficial effect of supplementing neonates with vitamin A at birth for reducing
mortality in the first half of infancy. Considering the absence of a clear indication of the biological mechanism and conflicting findings
from individual studies in settings with varying levels of maternal vitamin A deficiency and infant mortality, and given four additional
ongoing trials with approximately 100,000 neonates being enrolled, we propose a delay in any policy recommendations for neonatal
vitamin A supplementation.
P L A I N L A N G U A G E S U M M A R Y
Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Vitamin A is an important micronutrient that is required for the maintenance of normal functioning of the human body. In the
developing world, many pregnant women are vitamin A-deficient. During pregnancy, additional vitamin A is required for the growth
of the baby and for providing stores in the baby’s liver. Deficiency of this micronutrient in the mother may also lead to its deficiency in
the baby and may result in adverse effects on the baby’s health. The benefits of giving vitamin A to children greater than six months of
age, in reducing death and adverse effects on health, have been established but no evidence of this beneficial effect is available in infants
one to five months of age. The potential benefits of vitamin A supplementation in the newborn period (during the first month of life)
is under investigation and the review identified seven studies including 51,446 newborns with the intervention group supplemented
with vitamin A in this period. There was a significant reduction in infant deaths at six months of age with the intervention when data
for all infants were analysed. A similar reduction in the risk was observed for term neonates whose data were available from a subset
of studies. These findings should be interpreted with caution because of the small number of studies used in these analyses and their
estimates were close to the null effect of vitamin A. There are several large studies being conducted. The data from these, when available,
will inform our analysis and help in establishing a definitive role of this intervention.
2Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Neonatal vitamin A supplementation versus control for the prevention of mortality and morbidity in term neonates in developing countries
Patient or population: mortality and morbidity in term neonates
Settings: low and middle income countries
Intervention: neonatal vitamin A supplementation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control neonatal vitamin A sup-
plementation
All cause infantmortality
at 6 months
Follow-up: 6 months
Low risk population RR 0.82
(0.68 to 0.99)
22721
(3 studies)
⊕⊕©©
low1,2,3
13 per 1000 11 per 1000
(9 to 13)
Medium risk population
15 per 1000 12 per 1000
(10 to 15)
High risk population
28 per 1000 23 per 1000
(19 to 28)
All cause infantmortality
at 12 months
child years of follow-up
Follow-up: 12 months
Low risk population4 Rate ratio 0.95
(0.72 to 1.26)
5732
(2 studies)
⊕⊕©©
low3,5,6
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13 per 1000 12 per 1000
(9 to 16)
High risk population4
46 per 1000 43 per 1000
(33 to 58)
Adverse events: Bulging
fontanelle
Follow-up: 3 days
Low risk population RR 1.38
(1.04 to 1.82)
3158
(2 studies)
⊕⊕⊕⊕
high3,7,8
25 per 1000 35 per 1000
(26 to 46)
High risk population
94 per 1000 130 per 1000
(98 to 171)
Adverse events: Vomit-
ing
Follow-up: 3 days
145 per 1000 128 per 1000
(107 to 152)
RR 0.88
(0.74 to 1.05)
3159
(2 studies)
⊕⊕⊕©
moderate7,8,9
Adverse events: Diar-
rhoea
Follow-up: 3 days
51 per 1000 47 per 1000
(39 to 56)
RR 0.92
(0.77 to 1.09)
3159
(2 studies)
⊕⊕⊕©
moderate7,8,10
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 The risk of bias assessment identified a possible issue over the stopping procedure in Klemm 2008. A higher rate of mortality was
observed in the placebo group after 2/3 participants had been randomised. This study dominated the analysis (65% weight).
2 The level of statistical heterogeneity between the results of the studies was moderate (I square 63%). The variation between the
studies may have been related to differences between the study populations and settings in terms of infant mortality rates and baseline
prevalence of vitamin A deficiency.
3 It should be noted that there are a number of ongoing studies. The funnel plots did not indicate substantial asymmetry. The review
concluded that firm policy recommendations could not be made until the studies are complete and contribute to the review.
4 The rate reflects the number of events per 1000 years of child follow-up.
5 Very high levels of statistical heterogeneity (I square 82%).
6 The 95% confidence intervals include a substantial reduction in rate of mortality by 28% (translating to a reduction of 4 and 13 events/
1000 child years in low and high risk populations), as well as a substantial increase in the mortality rate of 26% (translating to an increase
of 3 and 12 events/1000 child years in low and high risk populations).
7 The population for these outcomes includes all infants (i.e. term and pre-term).
8 Only two of the included studies reported this outcome. The authors note that data reported on this outcome specified different
timepoints and could not be formally used in the meta-analysis.
9 In view of the high event rates for this outcome, the width of the confidence intervals lead to substantial variation in the absolute effect
from a protective effect of vitamin A to an increase in the risk of vomiting.
10 There was a high level of statistical heterogeneity (I square 80%).
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B A C K G R O U N D
Description of the condition
Vitamin A deficiency is considered to be a major public health
problem in the developing countries (WHO 2000; WHO 2009).
Globally, 9.8 million pregnant women are affected by night blind-
ness, with more than 19 million having low serum retinol con-
centrations (< 0.70 µmol/L). Night blindness affects 5.2 mil-
lion preschool children and an estimated 190 million have low
serum retinol concentrations. The prevalence of low serum retinol
concentrations in pregnant women is highest in South-East Asia
(17.3%) followed by Africa (13.5%), whereas the prevalence of
night blindness is approximately the same in the two regions (9.9%
in South-East Asia versus 9.8% in Africa) (WHO 2009).
Deficiency of vitamin A may be secondary to decreased ingestion,
defective absorption and altered metabolism; or increased require-
ments. Factors such as lowdietary fat intake or intestinal infections
may also interfere with the absorption of vitamin A. Vitamin A
deficiency is the most important cause of childhood blindness and
contributes significantly to morbidity and mortality from com-
mon childhood infections. It is a significant contributing factor
in the 2.2 million diarrhoea deaths each year among children un-
der five years of age, and in the nearly one million measles deaths
(SOWC 1998).
Description of the intervention
Vitamin A is an essential micronutrient that is required for the
maintenance of normal functioning of the human body. It was the
first fat soluble vitamin to be discovered and has been known to
be an important dietary constituent for nearly a century (Hopkins
1912; McCollum 1915). Vitamin A is part of a family of com-
pounds called retinoids; the naturally occurring retinoids are
retinol, retinal and retinoic acid. For human physiology, retinol is
the predominant formand11-cis-retinol is the active form.The in-
active retinoids, also known as provitamin A, are produced as plant
pigments and are called carotenoids. Although many carotenoids
occur in foods, approximately only 50% can be metabolized into
the active retinoid forms. Beta-carotene, a retinol dimer, has the
most significant provitamin A activity. Vitamin A is stored in the
liver as retinyl esters and, when needed, is transported into blood
where it is carried by retinol binding protein (RBP) for delivery
to other tissues (Shenai 1993).
Vitamin A is important for the normal functioning of the vi-
sual system, immune response, gene expression, reproduction, em-
bryogenesis and hematopoiesis (Sommer 1996). It is essential for
the maintenance of normal epithelial tissues throughout the body
(Wolbach 1925). Preformed vitamin A is found only in animal
foods such as liver, fish and dairy products (such as milk, cheese
and butter); it constitutes 65% to 75% of the dietary vitamin A
intake. The remaining dietary vitamin A comes from carotenoids
present in plant sources such as carrots, dark green leafy vegetables,
red and orange fruits and red palm oil. The Recommended Di-
etary Allowances (RDAs) for vitamin A vary with age. For healthy
breast-fed infants up to six months of age the average RDA is 400
µg/d, and for infants seven to 12 months of age the RDA is 500
µg/d. For children one to three years and four to eight years old,
the RDA is 300 µg/d and 400 µg/d, respectively (DRI 2001).
Routine consumption of large amounts of vitamin A over a period
of time can result in toxic symptoms which include liver dam-
age, headaches, vomiting, skin desquamation, bone abnormalities,
joint pain and alopecia. Hypervitaminosis A appears to be due to
abnormal transport and distribution of vitamin A and retinoids
that is caused by overloading of the plasma transport mechanisms
(Smith 1976). A very high single dose can also cause transient acute
toxic symptoms that may include a bulging fontanelle in infants;
headaches in older children and adults; and vomiting, diarrhoea,
loss of appetite and irritability in all age groups. Toxicity from in-
gestion of food sources of preformed vitamin A is rare (Hathcock
1997).
How the intervention might work
During pregnancy, women need additional vitamin A (an addi-
tional increment of 100 µg/day above basal requirements during
the full gestation period) to sustain the growth of the fetus and to
provide a limited reserve in the fetal liver as well as to maintain
the woman’s own tissue growth. Because therapeutic levels of vi-
tamin A are generally higher than preventive levels, the safe intake
level recommended during pregnancy is 800 µg retinol equivalents
(RE)/day.Women who are or whomight become pregnant should
carefully limit their total daily vitamin A intake to a maximum
of 3000 µg RE (10,000 IU) to minimize the risk of fetal toxicity
(WHO/NUT 1998). Infants have very low levels of vitamin A
stored in the liver at birth and are dependent on breast milk as a
source of vitamin A in the first few months of life. Thus, maternal
vitamin A deficiency during lactation, early weaning or artificial
feeding may result in vitamin A deficiency in infants (Underwood
1994). The physiologic vitamin A needs of infants born to vitamin
A-adequate mothers and fed breast milk with adequate vitamin
A (in excess of 30 µg/dL or 1.05 µmol/L) are met for at least the
first six months of life (Underwood 1994). Because of the need for
vitamin A to support the growth rate in infancy, which can vary
considerably, a requirement estimate of 180 µg RE/d seems ap-
propriate. Average consumption of human milk by such infants is
about 750 ml/day during the first six months (WHO/NUT/98.1
1998). Assuming an average concentration of vitamin A in human
milk of about 1.75 mmol/l, the mean daily intake would have to
be about 375 µg RE, which is therefore the recommended safe
level.
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Why it is important to do this review
The role of vitamin A supplementation in children greater than six
months of age is well established (Beaton 1993; Imdad 2010; Rice
2004). Beaton and colleagues in their meta-analysis showed that
vitamin A supplementation in children six months to five years
of age significantly reduced mortality by 23% (Beaton 1993). A
recent Cochrane Review concluded that two oral doses of 200,000
IU of vitamin A on consecutive days in children less than two
years of age with measles were associated with a reduced risk of
overall mortality (RR 0.18; 95% CI 0.03 to 0.61); similarly with
pneumonia-specific mortality (RR 0.33; 95% CI 0.08 to 0.92)
(Huiming 2005). The World Health Organization (WHO) rec-
ommends administration of vitamin A during vaccination con-
tacts in order to prevent vitamin A deficiency (WHO 1998). The
policy has been to supplement 100,000 IU of vitamin A at the
earliest possible opportunity after six months of age. However,
it has now been recommended that an additional 50,000 IU of
vitamin A be administered with each of the diphtheria-tetanus-
pertussis (DTP) and polio vaccinations, which are usually given
at six, 10 and 14 weeks of age (Sommer 2002). National and re-
gional programmes of vitamin A supplementation are in place in
over 60 countries worldwide and target children greater than six
months of age. These programs are not only highly effective in
reducing mortality and morbidity but, in countries in which vi-
tamin A deficiency constitutes a public health problem, the pro-
grammes appear to be among themost cost-effective public health
interventions available. Such programs address child survival in
children greater than six months of age; this group accounts for
a quarter of under five years of age deaths. In order to address
the major proportion of deaths in children under five, children
less than six months of age should be targeted. Supplementation
with vitamin A between one and five months of age has not been
found to have a beneficial effect (Daulaire 1992; Rahman 1995;
WHO/CHD 1998). Supplementation of neonates has been sug-
gested as a feasible approach to bolstering body stores of vitamin
A in early infancy and, therefore, having an impact on mortality
and morbidity (Sommer 1995; Sugana 1978).
O B J E C T I V E S
To evaluate the role of vitamin A supplementation in term
neonates in developing countries with respect to the prevention of
mortality and morbidity.
Weprespecified the following subgroups to investigate heterogene-
ity:
1. maternal vitamin A supplementation;
2. birth weight of neonates;
3. HIV status of the mother and infant;
4. dose and frequency of vitamin A used;
5. high baseline infant mortality;
6. co-morbidities;
7. timing of vitamin A supplementation (either within the
first 48 to 72 hours or later).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials, both individual and cluster ran-
domised and irrespective of publication status and language, eval-
uating the effects of vitamin A supplementation in term neonates
in developing countries were included in the review. Studies using
factorial design and quasi-randomised trials were also included.
Types of participants
All term neonates (born between 37 to 42 weeks of gestational
age) up to 28 days after birth were included.
Types of interventions
Supplementationwith vitaminAwithin the first 28 days of life was
compared against a control (placebo or no supplementation). Any
trial with continued supplementation beyond the first 28 days of
life was excluded from the review. Co-interventions, if any, should
have been identical in the two groups.
Types of outcome measures
Primary outcomes
1. All-cause infant mortality at six and 12 months
Secondary outcomes
1. Cause-specific infant mortality associated with acute
respiratory infections and diarrhoea at six and 12 months
2. Infant morbidity at six months of age, associated with acute
respiratory infections and diarrhoea, measured as at least one
episode of morbidity
3. Biochemical indicator values of vitamin A deficiency
(vitamin A deficiency measured as serum retinol < 0.70 µmol/L)
4. Blindness and signs of xerophthalmia (Bitot’s spots and
corneal lesions)
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5. Mean haemoglobin level or anaemia defined as
haemoglobin less than the age-specific cut-off value as stated by
the authors
6. Adverse events reported in trials due to vitamin A toxicity
such as bulging fontanelles, vomiting and diarrhoea
Search methods for identification of studies
See: Cochrane Neonatal Review Group methods used in reviews
We used the standard search strategy of the Cochrane Neona-
tal Review Group. The Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library, 14 June 2010), EM-
BASE and MEDLINE (1966 to May 2010) via PubMed were
searched using the following search terms: (Newborn OR infan*
OR neonat*) AND (vitamin A OR retino*) Limit: publication
type clinical trial.
We limited the searches to human studies. We did not apply any
language restrictions. We also searched related conference pro-
ceedings for relevant abstracts. We contacted organizations and re-
searchers in the field for information on unpublished and ongoing
trials.We searched reference lists of all trials identified by the above
methods. For further identification of ongoing trials the websites
www.clinicaltrials.gov and www.anzctr.com were searched.
Data collection and analysis
Selection of studies
Two review authors, Batool Haider (BAH) and Zulfiqar Bhutta
(ZAB), independently assessed all the potential studies we iden-
tified as a result of the search strategy for inclusion. We resolved
any disagreement through discussion.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors (BAH and ZAB) extracted the data using the agreed form.
We resolved discrepancies through discussion. Data were entered
into the Review Manager software (RevMan 2008) and checked
for accuracy.
Assessment of risk of bias in included studies
Two review authors (BAH and ZAB) independently assessed the
risk of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008). We resolved any disagreement by discussion.
(1) Sequence generation (checking for possible selection
bias)
We described for each included study the method used to generate
the allocation sequence, if it was in sufficient detail to allow an
assessment of whether it should produce comparable groups.
We assessed the method as:
• low risk (adequate) (any truly random process, e.g. random
number table; computer random number generator);
• high risk (inadequate) (any non-random process, e.g. odd
or even date of birth; hospital or clinic record number);
• unclear risk.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence if in sufficient detail to determine whether
intervention allocation could have been foreseen in advance of or
during recruitment, or changed after assignment.
We assessed the methods as:
• low risk (adequate) (e.g. telephone or central
randomisation; consecutively numbered sealed opaque
envelopes);
• high risk (inadequate) (open random allocation; unsealed
or non-opaque envelopes, alternation; date of birth);
• unclear risk.
(3) Blinding (checking for possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. Studies were judged at low risk
of bias if theywere blinded or if we judged that the lack of blinding
could not have affected the results.
We assessed the methods as:
• low risk (adequate), high risk (inadequate) or unclear risk
for participants;
• low risk (adequate), high risk (inadequate) or unclear risk
for personnel;
• low risk (adequate), high risk (inadequate) or unclear risk
for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis
at each stage (compared with the total number of randomised
participants), reasons for attrition or exclusion where reported,
and whether missing data were balanced across groups or were
related to outcomes. We assessed methods as:
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• low risk (adequate);
• high risk (inadequate);
• unclear risk.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk (adequate) (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk (inadequate) (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so cannot be used; the study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk.
(6) Other sources of bias
We described for each included study any important concerns we
have about other possible sources of bias. We assessed whether
each study was free of other problems that could put it at risk of
bias as:
• yes;
• no;
• unclear.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2008). We
explored the impact of the overall risk of bias by undertaking sen-
sitivity analysis for primary outcomes. We considered a study to
be of high quality if it was judged to have adequate sequence gen-
eration and allocation concealment, with either adequate blinding
or methods for dealing with incomplete outcome data.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratios
or rate ratios with 95% confidence intervals (CI).
Continuous data
There were no continuous outcomes in this review.
Unit of analysis issues
There were two cluster randomised trials (Klemm 2008; West
1995) included in this review. Klemm et al reported that the ob-
served design effect was 0.9%. InWest 1995, the 95% confidence
intervals (CIs) of the effect estimates were inflated by 10% to ac-
count for the impact of design on the study findings. We estimated
that the 10% increase in the 95% CIs gave an intracluster corre-
lation coefficient (ICC) of 0.04 for the cohort of infants adminis-
tered vitamin A.
Data synthesis
We analysed the data using a generic inverse variance approach to
meta-analysis, using Review Manager software (RevMan 2008),
and generated risk ratio or rate ratio estimates with 95%CIs for the
dichotomous outcomes. For this approach, the data were entered
as natural logarithms (as log risk ratios and SE of log risk ratio or
log rate ratios and SE of log rate ratio) for each individual study,
with data either extracted from the published papers or obtained
from the authors if not presented in the papers. Data used for the
infant mortality analyses along with their source are presented in
’Additional tables’. We used the fixed-effect method for combin-
ing data where trials were examining the same intervention and
the trial populations and methods were judged to be sufficiently
similar.
The review objective was to evaluate the effect of vitamin A sup-
plementation in term neonates. The studies included in this re-
view had enrolled all births that were identified in their study set-
tings without using a restriction for gestational age, of either <
37 or ≥ 37 weeks, which would have allowed us to use the term
data only. Birthweight was used as a criterion in two studies: Benn
2008 enrolled normal birthweight neonates (birthweight ≥ 2500
g) andBenn 2010 recruited lowbirthweight neonates (birthweight
< 2500 g) only. Data for term neonates was presented separately
only in the published paper of one study, for the infant mortality
outcome at six months (Klemm 2008), whereas mortality data
for term neonates only for other studies was obtained by con-
tacting the study authors. Information about the gestational age
was not available in West 1995 (KeithWest; personnel communi-
cation 2008). Considering the small number of studies included
in the review and the availability of data for primary outcomes,
we analysed data for term neonates, where available, followed by
the analysis for all infants. For all secondary outcomes, data in
published papers were presented for all infants together and have
been analysed as such. As the inclusion criterion of Benn 2008 was
birthweight at least 2500 g, we assumed that a greater proportion
of neonates would be term babies and have analysed its data as
such in our term neonate analysis. We used the term ’all infants’
to refer to aggregated term and preterm infants data throughout
this review.
There were two studies which hadmaternal supplementation with
vitamin A, either in the postpartum period (Malaba 2005) or dur-
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ing pregnancy (Klemm 2008). Malaba et al randomised mother-
infant pairs to the four treatment arms (described in detail in the
table ’Characteristics of included studies’) whereas Klemm et al
randomised neonates within each of three previously randomised
treatment arms of a maternal supplementation trial of vitamin
A. This resulted in two neonatal treatment arms in Klemm 2008
which were balanced across the maternal supplementation arms.
Both studies reported no significant interaction between maternal
and neonatal supplementation with vitamin A and we have used
data for all neonates included in these studies on the basis of their
randomisation to the neonatal vitamin A intervention or control
group.
Subgroup analysis and investigation of heterogeneity
We measured heterogeneity among the trials by calculating the I2
statistic. Values of the I2 statistic greater than 50%were considered
to represent substantial heterogeneity, in which case we planned
to explore heterogeneity by undertaking prespecified subgroup
analysis. However, the small number of studies included in the
review precluded any evaluation of heterogeneity, when identified.
Weplanned to investigate publicationbias for outcomeswithmore
than 10 included studies. However, we did not investigate the
presence of this bias as the number of studies included was small.
R E S U L T S
Description of studies
Included studies
Seven studies including 51,446 neonates were included in this
review.
The study by Humphrey et al was conducted in a single tertiary
care hospital in Indonesia (Humphrey 1996) as a safety trial for
vitamin A supplementation at the time of birth. This was a ran-
domised double blind placebo controlled trial of 2067 infants with
birthweight > 1500 g and without any critical illness. The infants
were randomly assigned to receive a single oral dose of vitamin
A (50,000 IU) or placebo within 24 hours of delivery. The two
groups were similar at baseline for maternal, infant and household
characteristics.
The study conducted by West et al (West 1995) in Nepal was part
of a large cluster randomised, double blind, placebo controlled
trial of vitamin A supplementation in preschool children. A total
of 11,918 infants less than six months of age, of which 1621 were
neonates, were enrolled and administered vitamin A (50,000 IU
in < one month old infants and 100,000 in one to five month old
infants) or placebo. Baseline characteristics of the two groups were
similar.
The study conducted in India byRahmatullah et al (Rahmathullah
2003)was also a randomised, double blind, placebo controlled trial
in which all live born infants resulting frompregnancies within the
participating villages were eligible for inclusion. A total of 11,619
newborn infants born to consenting mothers who were residing
in the study area were enrolled. Infants were given two doses of
vitamin A or placebo with the first dose being administered within
the first 48 hours of delivery and the second dose within 24 hours
of the first dose. Baseline characteristics of the families, mothers
and infants were similar between the treatment groups.
The Zimbabwe study (Malaba 2005) was a randomised, double
bind, placebo controlled trial using a two by two factorial de-
sign. Mother-infant pairs were eligible for inclusion if the mother
planned to reside in the study area after delivery. None of the two
had any life threatening illness and the infant’s birthweight was >
1500 g. Around 14,110 infant-mother pairs were enrolled within
96 hours of delivery and were assigned to either of the following
groups: Aa (vitamin A supplementation to both the mother and
infant), Ap (vitamin A to the mother and placebo to infant), pa
(placebo to mother and vitamin A to infant) and pp (placebo to
both the mother and infant). The vitamin A dose for mothers was
400,000 IU and for infants it was 50,000 IU. All the treatment
groups were similar at baseline for maternal, household and other
related variables.
The study conducted byKlemmet al inBangladesh (Klemm2008)
was a cluster randomised, double bind, placebo controlled trial
which was nested within an ongoing parent trial of vitamin A sup-
plementation in pregnant women. All infants born to consenting
mothers of the original trial were included in the current trial. A
total of 15,948 infants were administered vitamin A (50,000 IU)
or placebo at home as soon as possible after birth. Baseline charac-
teristics of the mothers and infants in this study were comparable
at baseline.
Two studies were conducted in Guinea Bissau by Benn et al. Benn
2008 was a randomised, double blind, placebo controlled trial
which included 4345 normal birthweight infants (birthweight at
least 2500 g). For births occurring at the national hospital or local
health centres, mothers were invited to participate in the study at
the time of Bacille Calmette-Guérin (BCG) vaccination. For home
births, mothers were invited to participate at the time of their visit
to the local health centres for BCG vaccination. All infants with
birthweight at least 2500 g, without any serious medical condi-
tion or malformation, for whom parental consent was available
were randomised to either oral drops of vitamin A (50,000 IU) or
placebo. The treatment groups were similar at baseline for various
baseline characteristics. The other study by these investigators was
conducted in parallel with Benn 2008. Benn 2010 was a two by
two factorial, randomised, double blind, placebo controlled trial
in low birth weight neonates (birthweight < 2500 g). This study
included 1736 neonates randomised to either 25,000 IU vitamin
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A or placebo, as well as to early BCG vaccine or the usual late
BCG vaccine.
See the table ’Characteristics of included studies’ for further details.
Ongoing studies
There are four ongoing studies that are being conducted in Pak-
istan, India, Ghana and Tanzania. All four studies are randomised,
double blind, placebo controlled trials, with the one in Pakistan
using a cluster randomised design.
The inclusion criteria for Pakistan 2008 were live born infants
without congenital malformations or serious birth injury from all
pregnancies within participating villages, with a sample size of
7,400 infants. The study was designed as an effectiveness trial with
vitamin A delivery through the Lady Health Workers program of
the government of Pakistan. Intervention included routine post-
partum care and vitamin A supplementation (50,000 IU) to the
newborn within 48 to 72 hours of birth whereas the control group
received routine postpartum care only. Outcomes to be evaluated
were all-cause and cause-specific infant mortality at six months,
incidence of serious infections (sepsis, pneumonia and diarrhoea),
measurement of serum retinol values and rates of breastfeeding in
the two groups. Recruitment and follow up for this study have
been completed and data analysis is in progress.
The studies being planned in India, Ghana and Tanzania also
aim to evaluate the effect of supplementation of 50,000 IU of
vitamin A against control. The Indian study is being conducted
in two districts in the state of Haryana with an estimated sample
size of 40,200 neonates (India 2010). All births in the study area
contacted by the enrolment team within the eligible age window
and with the parent’s consent to participate will be included. The
eligible age window has been defined as up to 60 hours after birth.
Outcomes that will be evaluated include infant mortality at six
months, mortality in the neonatal period (during the first month
of life); incidence of severe morbidity, defined as hospitalizations
due to any illness in the first six months of infancy; potential
adverse effects of vitamin A; and vitamin A status in a subgroup
of newborns at two weeks and three months of age and their
caregivers.
The methodologies of the studies in Ghana and Tanzania were
found to be similar. The Ghana study will be conducted in seven
contiguous districts in the Brong Ahafo region of central rural
Ghana (Ghana 2010) with a target sample size of 28,000 neonates.
The Tanzanian study will be conducted in Dar-es-Salaam and the
Kilombero and Ulanga districts in Ifakara (Tanzania 2010). The
estimated sample size for this study is 32,000 neonates. Inclusion
criteria in both studies are all births in the study area that are
contacted by the study team on the day of birth or in the next two
days. Both singleton and multiple births are eligible for inclusion
and each infant will be provided a unique identification number.
Intervention includes vitamin A 50,000 IU once orally within the
first three days of life, keeping a minimum period of two hours
between birth and dosing. Similar outcomes will be evaluated in
the two studies, which are all-cause infant mortality assessed at six
months of age, all-cause neonatal mortality assessed at one month
of age, incidence of severe morbidity defined as hospitalisations
due to any illness in the first six months of infancy, potential
adverse effects of vitamin A, and vitamin A and C reactive protein
(CRP) status in a subsample of infants at two weeks and three
months of age.
See the table ’Characteristics of ongoing studies’ for further details.
Excluded studies
Two studies were excluded from the review (Bezzera 2009;
Bhaskaram 1998). Bezzera 2009 included vitamin A supplemen-
tation of mothers only in the immediate postpartum period; their
neonates were not supplemented. Bhaskaram 1998 supplemented
mothers only with vitamin A within 24 hours of delivery while
all neonates were given oral poliovirus vaccine (OPV) between 48
and 72 hours after birth.
Risk of bias in included studies
Three studies adequately randomised neonates to the treatment
groups (Benn 2008; Benn 2010; Malaba 2005) with a clear de-
scription of the method used for generating the randomisation
sequence. Four studies did not provide sufficient details to allow
judgement of the adequacy of their methods (Humphrey 1996;
Klemm 2008; Rahmathullah 2003; West 1995). The method of
allocation concealment was clearly described in four studies (Benn
2008; Benn 2010; Humphrey 1996; Malaba 2005) whereas it was
not described in sufficient detail in Klemm 2008, Rahmathullah
2003 and West 1995. Blinding of participants, study personnel
and outcome assessors was clearly described and achieved in all
included studies. The post randomisation attrition and exclusion
of participants was: 1.6% (Benn 2008), 18.7% (Benn 2010), 11%
(Humphrey 1996), 7% (Klemm 2008), 41.8% (Malaba 2005)
and 18.9% (Rahmathullah 2003), with reasons for attrition and
exclusionof the participants described in the papers. Exclusion and
attrition were 1.04% in West 1995 and details of these were not
provided. Evaluation of selective outcome reporting by reviewing
either trial registration documents, if available, or methodology in
published papers showed that all trials have reported their findings
for prespecified or expected outcomes except for Humphrey 1996
where it was unclear. We identified three trials with potential high
risk of other bias: Benn 2008 and Benn 2010 conducted post hoc
analyses after assuming that vitamin A might be more beneficial
to boys whereas Klemm 2008 was terminated after randomisation
of two-thirds of the planned number of infants due to the signif-
icantly higher mortality in the control group. Malaba 2005 was
found to be free of other bias and the risk of other bias was uncer-
tain in the remaining three trials due to insufficient information
(Humphrey 1996; Rahmathullah 2003; West 1995).
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See the table ’Characteristics of included studies’ for further details
on risk of bias in included studies. A graphical presentation of our
individual judgments per item per study is provided in Figure 1
and a summary graph is given in Figure 2.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison Neonatal
vitamin A supplementation versus control for the prevention of
mortality and morbidity in term neonates in developing countries
A summary of findings table based on the outcomes in term
neonates has been included in this review, which is in accordance
with the methodology recommended by GRADE (Summary of
findings for the main comparison).
Neonatal vitamin A supplementation versus placebo
Primary outcomes
All-cause infant mortality at six months of age
An overview of the type and source of data for this outcome is
presented in Table 1.
Six included studies (Benn 2008; Benn 2010; Humphrey 1996;
Klemm 2008; Malaba 2005; Rahmathullah 2003) measured in-
fant mortality at six months of age.West 1995 measuredmortality
at four months of age and this data has been included in the six
month mortality analysis.
All-cause infant mortality at six months of age: risk ratios
based on cumulative risk (%) (Outcome 1.1)
Data from five studies were measured as risk ratios based on cu-
mulative risk.
The pooled estimate of data for term infants from three studies
(Humphrey 1996; Klemm 2008; Malaba 2005) suggests that the
risk of death from any cause at six months of age for neonates who
were supplemented with vitamin A is 18% lower than control,
which is statistically significant (typical RR 0.82; 95% CI 0.68 to
0.99) (Analysis 1.1.1). The level of statistical heterogeneity in this
analysis was 63%. As the number of studies included was small, a
subgroup analysis to investigate heterogeneity was not considered
reliable. Given substantial statistical heterogeneity and the small
number of included studies, these findings should be interpreted
with caution.
The pooled estimate of the data for all infants from five studies
(Humphrey 1996; Klemm 2008; Malaba 2005; Rahmathullah
2003; West 1995) showed a statistically significant reduction of
14% in the risk of death fromany cause for neonates supplemented
with vitamin A as compared to control (typical RR 0.86; 95% CI
0.77 to 0.97). The level of statistical heterogeneity for this analysis
was less than 50% (I2 39%) (Analysis 1.1.2).
There was only one high quality study included in these analyses
(Malaba 2005), hence a sensitivity analysis on the basis of study
quality was not undertaken.
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All-cause infant mortality at six months of age: rate ratios
(per years of follow up) (Outcome 1.2)
Data from four studies were analysed as rate ratios (per year of
follow up).
Pooled estimates for term neonates from Benn 2008 and
Rahmathullah 2003 showed no evidence of a significant effect on
the rate of death from any cause at six months of age in those that
received vitamin A as compared to control (typical rate ratio 0.91;
95%CI 0.73 to 1.13) (Analysis 1.2.1). Analysis for all infants data
from four studies (Benn 2008; Benn 2010; Rahmathullah 2003;
West 1995) also did not reach statistical significance (typical rate
ratio 0.91; 95% CI 0.77 to 1.06) (Analysis 1.2.2). The levels of
statistical heterogeneity were: I2 statistic 51% and 28% for term
and all infants analyses, respectively.
Analysis of two high quality studies showed similar effects of vi-
tamin A on the rate of death at six months as compared to con-
trol (typical rate ratio 0.89; 95% CI 0.75 to 1.05) (Rahmathullah
2003; Benn 2008; Benn 2010) (data not shown).
All-cause infant mortality at 12 months of age (Outcomes
1.3 and 1.4)
An overview of the type and source of data for this outcome is
presented in Table 2.
Four included studies (Benn 2008; Benn 2010; Humphrey 1996;
Malaba 2005) measured infant mortality at 12 months of age.
Analysis of term neonate data from two studies as rate ratios (
Benn 2008; Humphrey 1996) showed no evidence of a significant
effect on infant mortality from any cause at 12 months of age in
neonates supplemented with vitamin A as compared to control,
with statistical heterogeneity of 82% (typical rate ratio 0.95; 95%
CI 0.72 to 1.26) (Analysis 1.4). Further subgroup analysis was
not undertaken due to the small number of studies included. The
pooled estimate for all infants data from four studies also showed
no evidence of a significant effect of supplementation of neonates
with vitamin A on infant mortality at 12 months of age compared
to controls (typical risk ratio 1.02; 95% CI 0.87 to 1.20; typical
rate ratio 1.03; 95% CI 0.87 to 1.23) (Analysis 1.4 and 1.4.2).
The level of statistical heterogeneity was lower than 50% (I2 49%
for both risk and rate ratios). Three high quality studies (Benn
2008; Benn 2010; Malaba 2005) showed similar effects on infant
mortality at 12 months of age (typical risk ratio 1.07; 95% CI
0.91 to 1.27) (data not shown).
Secondary outcomes
Cause-specific infant mortality at six months of age:
diarrhoea and acute respiratory infections (Outcomes 1.5
and 1.6)
Infant mortality related to diarrhoea and acute respiratory infec-
tions at sixmonths of age wasmeasured by two studies (Humphrey
1996; Rahmathullah 2003). Data for all infants for Humphrey
1996 were measured as risk ratios based on cumulative risk, which
showed no significant effect of vitamin A supplementation on
diarrhoea and respiratory infections as compared to control (di-
arrhoea-specific infant mortality: risk ratio 0.20; 95% CI 0.02
to 1.68; and acute respiratory infection-specific infant mortality:
risk ratio 0.66; 95% CI 0.11 to 3.91). Data for all infants from
Rahmathullah 2003 were presented as rate ratios (per years of fol-
low up) and showed a similar non-significant effect of vitamin A
on the rate of diarrhoea-specific and acute respiratory infection-
specific infant mortality at six months of age as compared to con-
trol (diarrhoea-specific infant mortality: rate ratio 0.67; 95% CI
0.32 to 1.39; and acute respiratory infection-specific infant mor-
tality: rate ratio 1.00; 95% CI 0.56 to 1.79).
Cause-specific infant mortality at 12 months of age:
diarrhoea and acute respiratory infections (Outcomes 1.7
and 1.8)
Infant mortality related to diarrhoea and acute respiratory infec-
tions at 12 months of age was measured by three studies (Benn
2008; Humphrey 1996; Malaba 2005).
Data for all infants for Humphrey 1996 were measured as risk
ratios based on cumulative risk and showed no evidence of a sig-
nificant effect of vitamin A on death due to diarrhoea and acute
respiratory infections as compared to control (diarrhoea-specific
infant mortality: risk ratio 0.40; 95% CI 0.08 to 2.03 and acute
respiratory infection-specific infantmortality: risk ratio 0.66; 95%
CI 0.11 to 3.95). Benn 2008 and Malaba 2005 analysed data for
all infants as rate ratios. Pooled data suggested no evidence of a
significant effect of vitamin A on diarrhoea-specific and acute res-
piratory infections-specific infant mortality at 12 months of age
as compared to control (typical rate ratios: 1.32; 0.80 to 2.16; I2
0%; and 1.10; 0.48 to 2.50; I2 0%, respectively).
Cause-specific infant morbidity at 6 months of age: diarrhoea
and acute respiratory infection (Outcomes 1.9 and 1.10)
Two trials (Malaba 2005; Rahmathullah 2003) measured infant
morbidity at six months of age as rate ratios (per year of follow
up). Pooled estimates showed no significant effect of vitamin A as
compared to control on the rate of diarrhoea and acute respiratory
infections in infants at six months of age (typical rate ratio: 1.05;
0.99 to 1.10; I2 0%; and 1.01; 95% CI 0.96 to 1.05; I2 85%,
respectively). A subgroup analysis to investigate heterogeneity was
not considered due to the small number of studies contributing
data to this analysis.
Vitamin A deficiency (Outcomes 1.11 and 1.12)
Vitamin A deficiency defined as serum retinol value < 0.70 µmol/
L was available for all infants from one study only (Benn 2008),
which showed no evidence of a significant effect of vitamin A
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supplementation on vitamin A deficiency as compared to control
(at 6 weeks: risk ratio 0.94; 0.75 to 1.19; and at four months: risk
ratio: 1.02; 0.64 to 1.62).
Anemia (Outcome 1.13)
The impact on anaemia was measured in only one study (Malaba
2005), for all infants born to both HIV positive and negative
women. Vitamin A supplementation in neonates did not lead to
a significant impact on anaemia (haemoglobin (Hb) < 105 g/L)
at 8 to 14 months of age (risk ratio 0.97; 95% CI 0.87 to 1.07)
compared to control.
Adverse events (Outcomes 1.14 and 1.15)
Data for adverse events in all infants during the first 48 to 72 hours
could be pooled only from two studies (Benn 2008; Humphrey
1996), and only one study (Benn 2008) presented adverse events
at one month of age. Pooled estimates suggested no evidence of
a significant increase in adverse events during the first 48 to 72
hours, specifically bulging fontanelle (typical risk ratio 1.38; 95%
CI 1.04 to 1.82), diarrhoea (typical risk ratio 0.92; 95% CI 0.77
to 1.09) and vomiting (typical risk ratio 0.88; 95% CI 0.74 to
1.05), in the vitamin A group versus the control group. Benn
2008 showed no evidence of a significant increase in adverse events
during the first month post supplementation (risk ratio diarrhoea
1.07; 0.46 to 2.51; and vomiting 1.22; 0.57 to 2.58).
Other outcomes
The included studies did not measure the impact of neonatal vi-
tamin A supplementation on blindness and xerophthalmia.
D I S C U S S I O N
The objective of this review was to evaluate the effect of supple-
menting term neonates with vitamin A as compared to unsupple-
mented controls. As the term neonatal outcome data were only
available for a small number of studies, and then for infant mor-
tality outcomes only, we analysed and presented estimates for both
term neonates (where specified) and all infants for the various pre-
specified outcomes. Our analysis for all infants provided evidence
of a 14% (95% CI 3% to 23%) reduction in the risk of death at
six months of age in the vitamin A supplemented group as com-
pared to the controls. This was statistically significant. Analysis of
the term neonatal outcome included data from a subset of studies
included in the all infant analysis and also showed a significant
reduction in the risk of death in the first six months of life (re-
duction of 18%; 95% CI 1% to 32%). These findings should be
interpreted with caution due to the small number of studies con-
tributing data to these analyses, statistical heterogeneity and wide
confidence intervals that are close to the null effect. Three studies
(Benn 2008; Benn 2010; Rahmathullah 2003) had analysed data
as rates (per year of follow up) which precluded their inclusion
in this analysis. They have been analysed separately, whereas the
study byWest et al did not include information on gestational age.
Further assessment of the effect in term neonates is needed, with
data for all studies included in the review.
Analysis of the effect on infant mortality at 12 months of age of
vitamin A supplementation in neonates provided no evidence of a
significant effect on this outcome. Of four included studies, only
one by Humphrey et al in Indonesia (Humphrey 1996) showed a
highly significant effect on mortality at the end of the first year of
life. Overall, the review findings suggest a potential effect of this
intervention in the first half of infancy only.
Deficiency of vitamin A is a major nutritional concern in many
countries of the world. All studies included in this review were
conducted in developing countries with varying levels of vitamin
A deficiency and infant mortality. The first trial of vitamin A in
neonates was conducted as a safety trial in Indonesia (Humphrey
1996). This trial had shown significant reduction in the risk of
mortality, with a difference in survival between the groups notable
after the first month of life and becoming consistent after four
months of age. However, maternal serum retinol levels from a sub-
set of this study population showed mean (± SD) levels of 1.79
(± 0.53) and 1.75 (± 0.56) µmol/L in the vitamin A and control
groups respectively, suggesting little vitamin A deficiency. The in-
fant mortality rate in the control group (7.2 per 1000 child years)
was well below that in the general population and the authors
state that the families included in their study were relatively priv-
ileged (Humphrey 1996). It has been suggested that though the
serum retinol levels were adequate, this finding does not preclude
low hepatic reserves in this study group (Tielsch 2008a). Of the
other included trials, two were conducted in India (Rahmathullah
2003) and Bangladesh (Klemm 2008), which are characterized by
high infant mortality and vitamin A deficiency. The trial in India
showed a reduction of 22% in the risk of infant mortality at six
months whereas the trial in Bangladesh showed a 15% reduction
in the vitamin A group compared with the control group. In the
Indian setting, 5% to 6% of included women reported a history
of night blindness, which is a clinical manifestation of vitamin A
deficiency, and it was not significantly different between the two
groups (P = 0.26). The authors noted that the impact on mortal-
ity was evident from two weeks of age and continued until three
months, after which no further effect was observed. Similar ob-
servations were noted in the Bangladesh trial, which reported a
difference in the mortality of infants as early as after the first week
of life that persisted till four months of age. There were approxi-
mately 9.5% of the pregnant women in each group who reported
night blindness in their most recent pregnancy. A subsample of
this study population was measured for serum retinol in the first
trimester and showed a suboptimal vitamin A status (defined as
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serum retinol < 1.05 µmol/L) in approximately 41% of women
in the vitamin A group and 36% of women in the control group.
These findings of an effect of vitamin A on the risk of mortality
between the early weeks of life until four months does indicate a
common biological mechanism of vitamin A.
Conflicting results were shown by studies conducted in Nepal,
Zimbabwe and Guinea Bissau. The Nepal trial (West 1995) was
conducted as part of a larger vitamin A supplementation trial in
preschool children. The infants supplemented in the neonatal pe-
riod did not show a significant effect on infant mortality, which
was evaluated at four months of age. To note, this study setting
was characterized by endemic vitaminA deficiency and high infant
mortality. This finding was in contrast to findings fromother stud-
ies conducted in similar settings. Studies conducted in Zimbabwe
(Malaba 2005) and Guinea Bissau (Benn 2008) reported non-sig-
nificant effects of vitamin A on both six and 12 months infant
mortality outcomes. Infant mortality was measured in the other
trial by Benn et al in Guinea Bissau (Benn 2010) at 12 months,
which also showed no effect on the outcome. The vitamin A sta-
tus of mothers provided evidence of minimal deficiency in these
study settings with mean (± SD) serum retinol values in a subset
of Zimbabwean women in the control group of 1.09 (± 0.29) and
1.19 (± 0.42) µmol/L at six weeks postpartum. In Guinea Bissau,
less than 1% women were found to have low retinol binding pro-
teins (retinol binding proteins < 1.11 µmol/L). This study also
measured serum retinol values in infants at six weeks and four
months of age and showed no evidence of an effect of vitamin A
supplementation on vitamin A deficiency. An important feature
of this trial was that all eligible children were provided free consul-
tations and essential drugs for any illness during the first year of
life. The mechanism through which vitamin A supplementation
in children older than six months of age improves survival has
partly been explained by a reduction in the severity rather than the
incidence of infections (Sommer 1996). We believe that provision
of free consultations and essential drugs for illnesses in the Guinea
Bissau trial masked any beneficial effect of vitamin A supplemen-
tation that would have occurred through reducing severe illness
episodes. The reasons for possible differences in the results of vi-
tamin A supplementation trials conducted in different geographic
regions are uncertain and could be a chance observation. How-
ever, these findings could represent genuine differences in popu-
lation attributable risks of micronutrient deficiencies. The studies
included neonates of mothers with varying levels of baseline vita-
min A deficiency, both low birth weight and normal birth weight
neonates and varying rates of baseline infant mortality. These fac-
tors could affect the generalizability of study findings. It should
be noted that in contrast to the observed benefits of vitamin A
supplementation among mothers in Nepal (West 1999), a large
trial of maternal vitamin A supplementation in Ghana (Kirkwood
2010) did not show any benefits.
Reasons for these conflicting findings are unclear and there is no
clear indication of the biological mechanisms through which vi-
tamin A could lower the risk of death when given in the neona-
tal period. Various mechanisms have been proposed. Newborns
have marginal reserves of vitamin A in their liver and they de-
pend on breast milk as a source of this vitamin in the first few
months of life. Hence, low maternal vitamin A levels translate
into vitamin A deficiency in the newborns (Underwood 1994).
Deficiency of vitamin A could also begin very early in life with
the colostrum being discarded or breastfeeding being inadequate.
Colostrum and early breast milk have been found to be very rich
sources of vitamin A, which can significantly augment vitamin
A stores in the neonates (Wallingford 1986). Along with inade-
quate breastfeeding, introduction of artificial feeds also hinders
with the establishment of good breastfeeding practices, thereby
denying infants of this critical source of vitamin A throughout the
breastfeeding period (Haskell 1999). Artificial feeds early in life
also increase the risk of gastrointestinal infections in these infants.
Vitamin A supplementation has also been proposed to have an
impact on infant mortality through the development and main-
tenance of the integrity of the intestinal and respiratory epithe-
lia, and enhanced local and systemic immunity (Sommer 1996;
Tielsch 2007). These pathways may provide an explanation of the
effect in settings where the practice of discarding colostrum, inad-
equate breastfeeding or artificial feeds and infections are common.
Alternatively, the early initiation of feeding of colostrum and ex-
clusive breastfeeding could explain an absence of a beneficial effect
of vitamin A received as a supplement. However, in this review we
could not study these proposedmechanisms as only a few included
studies presented limited information on breastfeeding practices
and the use of artificial feeds.
There has been considerable debate on the issue of supplement-
ing neonates with vitamin A due to conflicting findings from the
studies and variability in the results of pooled analyses (Abrams
2008; Bhutta 2008; Gogia 2009; Sachdev 2008; Tielsch 2008a).
The current review includes data from several new studies pub-
lished since these earlier reviews and additional data that were
obtained by contacting the study authors. Our findings corrob-
orate those published in the earlier Lancet Undernutrition Series
(Bhutta 2008) that included three neonatal supplementation trials
published until then and used available data for analysing infant
mortality outcomes separately at six months and 12 months. It
showed a reduction of 20% (95% CI 4% to 34%) in the vitamin
A supplemented group compared to the unsupplemented control
group at six months of age. The earlier review also showed a non-
significant impact of vitamin A on infant mortality at 12 months
of age compared to the unsupplemented control (RR 0.90; 95%
CI 0.61 to 1.32). A similar review by Gogia et al (Gogia 2009)
analysed infant mortality data from six trials by pooling all deaths
between the period of initiation of intervention till the last follow
up, either at six or 12 months, and suggested no protective effect
on mortality during the first year of life (RR 0.92; 95% CI 0.75
to 1.12). We believe that such an approach would mask any bene-
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ficial effects of the intervention in early infancy and could also be
influenced by routine vitamin A supplementation practices after
six months of age in the given population. Given that vitamin A
supplementation to infants after six months of age is relatively well
established in developing countries, adjunctive benefits of neona-
tal vitaminA supplementation could provide complementary ben-
efits in young infants.
Limited data were available for the outcomes of cause-specific
mortality and morbidity; and vitamin A deficiency, measured as
serum retinol values in infants. Data on adverse events, specifically
bulging fontanelle, vomiting or diarrhoea, were also limited and
showed no significant increase within the first 48 to 72 hours of
supplementation. An evaluation of these outcomes is needed with
the inclusion of data from all studies that havemeasured these out-
comes and additional new trials that are being planned in Ghana
(Ghana 2010), India (India 2010) and Tanzania (Tanzania 2010).
These trials have been designed to evaluate the effect of 50,000
IU of vitamin A on infant mortality at six months of age, their
primary outcome. Another smaller effectiveness trial in Pakistan
(Pakistan 2008) has completed recruitment and follow up and the
data are being analysed. These additional trials will greatly con-
tribute towards the evidence base and consensus on the value or
otherwise of neonatal vitamin A supplementation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Considering the high burden of deaths of children under the age of
five years in developing countries, and mortality in infancy being
a major contributory cause, it is critical to obtain sound scientific
evidence of the effect of vitamin A supplementation in the neona-
tal period on infant mortality and morbidity. Evidence provided
in this review does indicate a potential beneficial effect of supple-
menting neonates with vitamin A at birth in reducing mortality in
the first half of infancy. Considering the absence of a clear indica-
tion of the biological mechanism through which vitamin A could
affect mortality in early infancy, substantial conflicting findings
from individual studies in settings with potentially varying levels
of maternal vitamin A deficiency and infant mortality; and given
that data from at least four new trials will be available in the fore-
seeable future, we propose to delay any policy recommendations
for neonatal vitamin A supplementation pending these findings.
Implications for research
Future research and trials should examine the effects of vitamin A
supplementation in the neonatal period on infant mortality in the
first half of infancy. These trials should also include measures of
maternal micronutrient status (vitamin A deficiency), the effect of
maternal vitamin A supplementation, dose of vitamin A, maternal
HIV status, breastfeeding patterns and breast milk vitamin A con-
centrations. Efforts should be made to stratify effects by age after
birth of vitamin A administration, prematurity and intrauterine
growth retardation. Research should also be conducted to identify
biologic mechanisms and indicators for vitamin A in reducing the
risk of death and to explain the differences observed in vitamin
A supplementation trials conducted in settings with varying levels
of baseline vitamin A deficiency.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Benn 2008
Methods Randomised, double blind placebo controlled trial.
Participants Inclusion criteria were infants weighing at least 2500 g at birth with no signs of overt
illness or malformations. Infants were recruited at the time of BCG vaccination. Number
of participants in vitamin A group was 2145 and that in the placebo was 2200
Interventions 0.5 ml vegetable oil, either containing 50,000 IU of vitamin A as retinyl palmitate and
10 IU vitamin E, or only 10 IU of vitamin E was given into the mouth of child at the
time of BCG vaccination
Outcomes Mortality at 12 month of age, cause specific mortality at 12 months of age, scar, in
vivo and ex vivo PPD response to BCG, retinol binding protein (RBP) concentration
at 6 weeks and 4 months of age (low RBP defined as serum retinol <0.70 micromol/
L) and adverse effects (bulging fontanelle, hospitalizations, irritability, fever, frequent
stools, vomiting, mother thinks the child is not well)
Notes Study was conducted in 6 urban districts in capital of Guinea-Bissau which is classified
as an area of subclinical vitamin A deficiency (by UNICEF) and high infant mortality.
The HIV prevalence among women in the study area was 3-5%
Since the authors did not have information about the gestational age at delivery and the
inclusion criteria was infants with birth weight of at least 2500 g, we included data as
such in the term neonate analysis assuming that a greater proportion of these were term
infants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “mother drew a lot from an enve-
lope prepared by the study supervisor. Each
envelope contained 100 lots 50marked “1”
and 50 marked “2” indicating from which
of two numbered bottles, “1” or “2,” the
child should receive the supplement”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “lots were folded, making it impos-
sible to tell whatwaswritten on thembefore
they were opened. A new envelope was not
taken into use before the previous envelope
had been completely emptied. The result
of the randomisation was noted on the in-
clusion form and the lot was stapled to the
inclusion form.”, “The dark glass bottles
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Benn 2008 (Continued)
were prepared at Skanderborg Pharmacy”
and “The code was kept at the pharmacy
until 12 months after the last child was in-
cluded”
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “blinding of mothers and assistants
was successful” and “assistants of the reg-
istration system and the special team were
unaware........vaccination card and follow
up forms” and “Apart from the randomi-
sation number, the bottles looked alike; we
judged small differences in taste and colour
of the contents as unimportant owing to
the recipients”
Comment: blinding of participants, study
personnel and outcome assessors probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was 1.6%. Reasons for attrition
and distribution in the two groups were
provided. Infant lost to follow up were sim-
ilar to those who were followed in baseline
anthropometric characteristics
Selective reporting (reporting bias) Low risk Comment: results of all expected outcomes
were presented in several publications of
the study
Other bias High risk A protocol was provided but post hoc anal-
yses were conducted after assuming that
Vit A might be more beneficial to boys.
The study was funded by the EU (ICA4-
CT-2002-10053), the Danish Medical Re-
searchCouncil, University of Copenhagen,
March of Dimes, and theVilleHeise Foun-
dation
Benn 2010
Methods Randomised, placebo controlled, two by two factorial trial.
Participants Inclusion criteria were infants weighing < 2500 g at birth with no severe malformations.
Number of participants in vitamin A group was 864 and that in the placebo was 872
Interventions Neonates < 2500 g at birth were assigned to 25,000 IU vitamin A as retinyl palmitate
and 10 IU vitamin E per 0.5ml oil or placebo which contained only 10 IU vitamin E
per 0.5ml oil, as well as to early BCG vaccine or the usual late BCG vaccine
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Outcomes Infant mortality and cause-specific infant mortality at 12 months
Notes • Study was conducted in 6 urban districts in capital of Guinea-Bissau which is
classified as an area having moderate to severe vitamin A deficiency (by WHO) and
high infant mortality.
• No evidence of an interaction between BCG and vitamin A supplementation in
neonates (P=0.73).
• Vitamin A was administered within the first 48 hours of life to 878 (51%) of the
1717 children.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly allocated in a two by
two factorial design” and“mother drew an
envelope
from a bag. Each bag was prepared... 12
marked ”no BCG 6,“ and 12 marked ”no
BCG 7“, ”The numbers 6 and 7 indicated
from which of two numbered bottles, 6 or
7, the child should receive treatment (that
is, either 25 000 IU vitamin A or placebo)
.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: ”The envelopes were closed and
non-transparent, making it impossible to
identify the allocation before the envelopes
were opened.“, ”The result of the randomi-
sationwas noted on the inclusion formand,
furthermore, the lot name was stapled on
the form.“ and ”The code of which treat-
ment was in which bottle was kept at the
pharmacy until 12 months after the last
child was included.“
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: ”numbers “6” and “7” indicated
from which of two numbered bottles, “6”
or “7,” the child should receive treat-
ment“, ”vitamin A and placebo bottles
looked alike“ and ”assistant and the nurse
who were responsible for the randomisa-
tion procedures had no idea which bottles
contained vitaminA orwhich had placebo“
and ”follow-up assistants were unaware of
the allocated treatment,
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Comment: blinding of participants, study
personnel and outcome assessors probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionwere 18.72%.Rea-
sons and distribution in the two groups
were provided. Numbers were balanced
across the treatment groups
Selective reporting (reporting bias) Low risk Comment: All expected outcomes, as per
protocol were reported or are under prepa-
ration (personal communication from the
author)
Other bias High risk A protocol was provided but post hoc anal-
yses were conducted after assuming that
Vit A might be more beneficial to boys.
The study was funded by the EU (ICA4-
CT-2002-10053), the Danish Medical Re-
searchCouncil, University of Copenhagen,
March of Dimes, and theVilleHeise Foun-
dation
Humphrey 1996
Methods Randomised placebo controlled trial.
Participants All neonates within 24 hours of birth were eligible for inclusion. Very low birthweight
babies (<1500 gm) and those with life threatening illnesses such as severe respiratory
distress syndrome,major congenital anomalies, paralysis, hypoglycaemia, hypocalcaemia,
clinical evidence of ischaemic hypoxia, or sepsis were excluded. A total of 2067 were
enrolled within the 24-hour inclusion period
Interventions One oral dose of 52 µmol vitamin A (as retinyl palmitate) plus 23 µmol vitamin E in the
treatment group. Placebo (<0.10 µmol vitamin A + 23 µmol vitamin E) in the control
group. Intervention n=1034 and placebo n=1033
Outcomes Mortality at 6 and 12 months of age, cause specific mortality at 12 month of age,
morbidity at 4 months of age, adverse effects of VAS (bulging fontanelle, vomiting,
fever, loose stool, irritability, intracranial haemorrhage, resistive index), development at
3 years of age
Notes • Infants born at Hasan Sadikin Hospital in Bandung, Indonesia, from June 18,
1992 to June 3, 1993 were considered.
• Mean age of dosing was 16.2 (SD=8.2) hours, 88.2% were dosed in first 24 hours
of life birth.
• Treatment groups were comparable at baseline.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “simple randomisation blocked within
the birth weight strata”
Comment: method used to generate the ran-
domisation sequence is not described in suffi-
cient detail to permit judgement
Allocation concealment (selection bias) Low risk Quote: “The randomisation scheme and coded
supplement packets were prepared by a team in
Baltimore, none of whom was involved in re-
cruitment or follow-up of infants in Indonesia”
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “supplements were individually coded,
odourless......follow-up of infants in Indonesia”
Comment: blinding of participants, study per-
sonnel and outcome assessors probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was 11% and reasons for it were pro-
vided. Distribution was balanced in the two
groups. Infants lost to follow up were not signif-
icantly different from those who were followed
Selective reporting (reporting bias) Unclear risk Comment: Insufficient information to permit
judgement
Adverse events were reported in a separate pub-
lication (Agoestina 1994)
Other bias Unclear risk Agoestina 1994 mentioned a protocol, but no
further details were provided. Supported by a
grant from John HopkinsUniversity and assis-
tance fromHoffmann-LaRoche industry (Basel,
Switzerland)
Klemm 2008
Methods Community based double masked, cluster randomised, placebo controlled trial
Participants Infants born to consenting mothers who were participating in the parent trial were
eligible for inclusion in the study
Vitamin A group infants whose mothers consented=8525
Placebo group infants whose mothers consented=8591
Infants of consenting mothers who had died before they could be supplemented by staff,
those who were born outside of the study area, and infants who could not be reached to
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receive a supplement after repeated staff visits during the first 30 days after birth were
excluded
Interventions Intervention= 50,000 IU of vitamin A or a placebo in oil given as soon as possible after
birth
Outcomes Infant mortality at 6 months of age and adverse effects
Notes • The trial was nested into an ongoing, placebo controlled, weekly, low-dose
vitamin A or beta-carotene supplementation trial among pregnant women, underway
since August 2001, to evaluate effects on pregnancy related mortality. The present
study began in January 2004 in districts of Gaibandha and Rangpur, Bangladesh.
• Randomisation of sectors was done in a manner to produce 2 infant
supplementation groups that were balanced across the maternal supplementation trial
arms. Interaction between maternal and vitamin A supplementation was non-
significant.
• Approx 84% supplemented within the first 48 hours after birth.
• Treatment groups were comparable at baseline.
• Analysis was adjusted for cluster design.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “cluster randomised” and “sectors
were listed in geographically contiguous or-
der and were randomised in blocks of 4”
Comment: method used to generate the
randomisation sequence is not described in
sufficient detail to permit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient detail to permit
judgement.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “sector-coded supplement”, “sup-
plements for both groups were opaque
gelatinous capsules identical in shape, size,
and colour containing edible oil”; “double-
masked”
Comment: blinding of participants, study
personnel and outcome assessors probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attrition was 7%. Reasons
and distribution in the two groups were
provided. Attrition and reasons for attrition
were balanced across the treatment groups
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Selective reporting (reporting bias) Low risk Comment: results of all outcomes men-
tioned in methods section of the published
paper and those in trial registration docu-
ment were presented in the paper
Other bias High risk Study halted before conclusion because
mortality on the placebo group was signifi-
cantly higher than intervention group after
2/3 of infants were randomised. Results ad-
justed by cluster effect. Source of funding:
John Hopkins University (GHS-A-00-03-
00019-00), Bill and Melinda Gates Foun-
dation
Malaba 2005
Methods Randomised placebo controlled two by two factorial design trial
Participants Mother and infant pairs enrolled within 96 hrs of delivery. Pairs were eligible if neither
of the pairs have an acutely life threatening condition, the infant was a singleton with
birthweight >1500gms, and the mother planned to stay in Harare after delivery
Mothers and infants were assigned into the following 4 groups
1. Mothers received 400,000 IU vitamin A and infants received 50 000 IU vitamin
A (Aa group)=3529
2. Mothers received 400,000 IU vitamin A and infants received placebo
(Ap group)=3529
3. Mothers received placebo and infants received 50,000 IU vitamin A
(Pa group)=3530
4. Both mothers and infants received placebo
(Pp group)=3522
Interventions Mothers received 400,000 IU vitamin A and infants received 50,000 IU vitamin A. Both
treatment and placebo contained a soy oil base with vitamin E (50 IU per maternal
capsule; 10 IU per infant capsule).
Outcomes Infant mortality at 6 and 12 months, cause-specific infant mortality at 12 months,
anaemia and haemoglobin in infants andMTCT of HIV in infants born toHIV positive
mothers
Notes • Zimbabwe is categorized by WHO as a high risk area for vitamin A deficiency.
HIV is endemic in Zimbabwe nearly 25% are HIV infected.
• From 25 November 1997 to 29 January 2000 in Harare, Zimbabwe.
• Three-quarters of the pairs received their treatment dose within 24 hours, and
94% received it within 48 hours of delivery.
• Interaction between maternal and infant vitamin A supplementation was not
significant (P=0.60).
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “study identification numbers were
randomly allocated to the treatment groups
by computer in blocks of 12”, “A separate
team at JohnsHopkinsUniversity prepared
the study capsule packets” and “Lists link-
ing the study number to the treatment were
kept in sealed envelopes and encrypted
computer files.”
Comment: probably done.
Allocation concealment (selection bias) Low risk Quote: “numbers were printed on adhesive
labels and affixed to amber-coloured zip-
lock plastic bags” and “capsules in the next
sequential bag were administered...... files”
Comment: probably done.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “capsules appeared identical”; “sep-
arate team at Johns Hopkins University
prepared the study capsule packets” and
“neither participants nor nurses who ad-
ministered the capsules or assessed out-
comes were aware of treatment group as-
signment”
Comment: blinding of participants, study
personnel and outcome assessors probably
done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Exclusions and attrition were 41.8%. Rea-
sons for exclusion includedbeingHIV-pos-
itive or HIV-indeterminate at baseline or
those who seroconverted. Reasons for attri-
tion were not provided
Selective reporting (reporting bias) Low risk Comment: results of all expected outcomes
were presented in various publications
Other bias Low risk “The ZVITAMBO Project was primarily
supported by the Canadian International
Development Agency (R/C Project 690/
M3688), the US Agency for International
Development (cooperative agreement no.
HRN-A-00-97-00015-00 between Johns
Hopkins University and the Office of
Health and Nutrition of the USAID), and
a grant from the Bill and Melinda Gates
Foundation (Seattle); additional support
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was provided by the Rockefeller Founda-
tion (NewYork) and BASF (Ludwigshafen,
Germany).”
Rahmathullah 2003
Methods Randomised, placebo controlled, community based trial.
Participants Live born infants that resulted from all pregnancies within participating villages were
eligible for participation. Pregnant women (>12 weeks) were identified for recruitment
from a variety of sources. The infants were randomly assigned to receive either the
intervention, or placebo
Exclusions after randomisation were stillbirths, miscarriages, delivery more than 20 km
outside the study area, and infants, who died before the study team reached
Interventions Infants received 24,000 IU of vitamin A twice within a 24 hour interval, beginning
within 48 hours of birth, or placebo
Outcomes Infant mortality at 6months, cause-specific mortality at 6months, incidence of common
morbidities and pneumococcal colonization
Notes • Conducted between June 1998 and March 2001 in two rural districts of Tamil
Nadu, southern India.
• These areas are characterized by endemic vitamin A deficiency.
• An expected infant mortality at 6 months of age of 52.5 per 1000 live births.
• Approximately 80% of participants were supplemented within 48 hours of birth.
• Treatment groups were comparable at baseline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomisation was at the individ-
ual level, stratified by geographical area in
blocks of four.”
Comment: method used to generate the
randomisation sequence is not described in
sufficient detail to permit judgement
Allocation concealment (selection bias) Unclear risk Quote: “For twins, the first born received
the assigned treatment and the second born
the other treatment. For triplets, the first
two born infants were handled as twins and
the third born received the originally as-
signed treatment.”
Comment: insufficient information pro-
vided to judge allocation concealment for
singleton births.However, for triplets (only
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2 in the data set), allocation concealment
did not hold
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “treatment doses were in an edible
oil solution packaged in identical gelatin
capsules” and “investigators, study staff,
and mothers were masked to the assigned
treatment”
Comment: blinding of participants, study
personnel and outcome assessors was prob-
ably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attrition was 18.9%. Rea-
sons and distributions in the two treatment
groups were reported. Mortality in infants
born alive but not enrolled was similar in
treatment groups
Selective reporting (reporting bias) Low risk Comment: outcomes mentioned in the
methods section were reported. All ex-
pected outcomes were presented in pub-
lished reports
Other bias Unclear risk Supported by a grant from John Hopkins
Universityand the Bill and Melinda Gates
Foundation
West 1995
Methods This trial was part of a large, cluster randomised, double masked, placebo controlled
community trial in Nepal
Participants Infants ≤5 months of age were eligible for inclusion. No exclusion criteria given
Interventions Intervention group received an oral dose of vitamin A [15,000 RE (50,000 IU) in 3
drops of oil for neonates (< 1 mo of age) and 30,000 RE (100 000 IU) in 6 drops of oil
for infants 1-5 mo of age or placebo [75 RE (250 IU) or 150 RE (500 IU), respectively].
A total of 11,918 infants (infants ≤5 months: intervention= 6086, control= 5832) were
enrolled. Among these, the distribution of neonates was: intervention=791, control=
830
Outcomes 4 month mortality, cause specific mortality and adverse effect noted after 24 hours of
dosing (vomiting, loose stools, fever, irritability, bulging fontanelles)
Notes • Was conducted in district of Sarlahi, Nepal between September 1989 and
December 1991.
• Evaluated the effect of VAS every 4 month on preschool child mortality.
• No information about gestational age and birth weight recorded and almost all
neonates were supplemented after the first week of life (Keith West; personnel
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communication 2008)
• Treatment groups were comparable at baseline.
• The 4-month mortality estimates have been included in the 6 month mortality
analysis
• This trial measured adverse effects approximately 24 hours after supplementation
whereas 2 other trials reported adverse effects 48-72 hours after supplementation.
Because of the difference in the timing of measurement of adverse effects, we did not
include the 24 hour measurements from this trial in the analysis. This trial found no
difference in the incidence of various adverse effects after 24 hours of supplementation
in the two groups of neonates.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Two hundred sixty-one wards in
29 contiguous village development areas
(VDAs) in the District of Sanlahi were
mapped and 33,000 households were num-
bered. After a random start, wards were sys-
tematically assigned, blocked on VDAs, for
infants to receive an oral dose of vitamin A.
”
Comment: method used for the first ran-
dom assignment is not described in suffi-
cient detail to permit judgement
Allocation concealment (selection bias) Unclear risk Comment: It is unclear as the wards were
assigned systematically
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “gelatinous capsules of identical ap-
pearance, size (8*16mm), and taste” and
“double-masked” and “capsule codes were
broken” (noted from methods section of
the larger trial paper)
Comment: blinding of participants, study
personnel and outcome assessors was prob-
ably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition among neonates was 1.04% rea-
sons for which were not provided. All anal-
yses performed on an intention-to-treat ba-
sis, that is, by randomised treatment group
irrespective of individual compliance to the
dosing regimen
Selective reporting (reporting bias) Low risk Comment: published reports included all
expected outcomes.
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Other bias Unclear risk Supported by a grant from John Hopkins
University and assistance from Hoffmann-
LaRoche industry (Basel, Switzerland). A
protocol is described but no details are pro-
vided
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bezzera 2009 This study included supplementation of mothers only with vitamin A supplements in the immediate postpartum
period and there was no supplementation of neonates with vitamin A
Bhaskaram 1998 This study included supplementation of mothers only with vitamin A supplements within 24 hours of delivery
while all neonates were given oral poliovirus vaccine (OPV) between 48 and 72 hours after birth
Characteristics of ongoing studies [ordered by study ID]
Ghana 2010
Trial name or title Efficacy of newborn vitamin A supplementation in improving child survival in rural Ghana: generation of
evidence necessary for informing global policy (Neovita)
Methods Double blind, randomised, placebo controlled trial in 7 contiguous districts (Kintampo North, Kintampo
South, Wenchi, Tain, Techiman, Nkoranza North and Nkoranza South) in the Brong Ahafo region of central
rural Ghana
Participants Inclusion criteria is all births in the study area that are contacted by the study team on the day of birth or in
the next 2 days. Both singleton and multiple births are eligible for inclusion in this study and each infant will
be provided with their own unique study identification number. Infants will be included even if they were
not identified during pregnancy surveillance
Exclusion criteria is if the neonate is unable to feed on offering feeds, as reported by the mother or the mother
does not intend to stay in the study area for at least 6 months
Interventions Intervention includes vitamin A 50,000 International Units (IU) once orally within the first 3 days of life
keeping a minimum period of 2 hours between the birth and the dosing
Placebo capsule of soy bean oil once orally within the first 3 days of life
Outcomes All cause early infant mortality (0-5 months) assessed at 6 months of age, all cause neonatal mortality (0-
1 month) assessed at 1 month, incidence of severe morbidity defined as hospitalisations due to any illness
in the first 6 months of infancy, potential adverse effects of vitamin A such as bulging fontanelle, vomiting,
irritability, fever, diarrhoea, inability to suck or feed, convulsions or any other condition that caused parents
to be concerned, in the 3 days period following administration of the supplement, and vitamin A and C
reactive protein (CRP) status of a subsample of infants at 2 weeks and 3 months of age
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Starting date Anticipated date of first participant enrolment: Aug 16, 2010
Contact information Karen Edmond
London School of Hygiene and Tropical Medicine, Keppel St London, WC1E7HT, UK
Email: karen.edmond@lshtm.ac.uk
Notes Target sample size: 28000
India 2010
Trial name or title Efficacy of Neonatal Vitamin A Supplementation in Improving Child Survival in Haryana, India: Generation
of Evidence Necessary for Informing Global Policy (NeoVitA Trial)
Methods Double blind, randomised, placebo controlled trial in two districts in the state of Haryana, India
Participants Inclusion criteria is all births in the study area that are contacted by the enrolment team within the eligible
age window (up to 60 hours of birth) and parent’s consent to participate
Exclusion criteria is neonate unable to feed on offering feeds, as reported by the mother or mother does not
intend to stay in the study area for at least 6 months
Interventions Intervention includes retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally
as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2
hours between the birth and the dosing
Placebo capsules will contain minute amounts of vitamin E in soybean oil
Outcomes Infant mortality at 6 months, mortality in the neonatal period (first month of life), incidence of severe
morbidity defined as hospitalizations due to any illness in the first 6 months of infancy; bulging fontanelle,
vomiting, irritability, fever, diarrhea, inability to suck or feed, convulsions or any other conditions that caused
parents to be concerned, in the 3 day period following administration of the supplement; and vitamin A
status in a subgroup of newborns and caregivers
Starting date June 2010
Contact information Nita Bhandari
Society for Applied Studies
New Delhi, Delhi, India, 110016
00 91 11 46043751-55 ext 201
Email: CHRD@sas.org.in
Notes Estimated enrolment: 40200
Estimated study completion date: November 2013
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Trial name or title Feasibility study of delivering a neonatal dose of vitamin A through the Lady Health Workers (LHWs)
program in Pakistan
Methods Cluster randomised, double blind, placebo controlled trial in Sukkhur and Jehlum districts in Pakistan
Participants Inclusion criteria is live born infants from all pregnancies within participating villages
Exclusion criteria is a child born with congenital malformation, serious birth injury, birth asphyxia, serious
infections, gestational age less than 32 weeks, birthweight less than 1500 gms and refuse to participate
Interventions Intervention includes routine postpartum care and vitamin A supplementation (50,000 IU) to the newborn
within 48-72 hours of birth
Control group receives routine postpartum care and placebo.
Outcomes All cause infant mortality at 6months, cause-specific infant mortality at 6months of age, serum retinol values,
rates of breastfeeding and incidence of serious infections (sepsis, pneumonia and diarrhoea)
Starting date January 2007
Contact information Zulfiqar A Bhutta
Division of Women & Child Health
The Aga Khan University, Karachi 74800, Pakistan
Email : zulfiqar.bhutta@aku.edu
Notes Estimated enrolment: 7400
Expected completion date: April 2010
Tanzania 2010
Trial name or title Efficacy of newborn vitamin A supplementation in improving child survival in Tanzania: generation of
evidence necessary for informing global policy
Methods Double blind, randomised, placebo controlled trial in Dar-es-Salaam, and Kilombero and Ulanga districts in
Ifakara, Tanzania
Participants Inclusion criteria is all births in the study area that are between two hours and two days of age, whose caretakers
confirm of intention to remain in the study areas for a minimum of six months thereafter. Both singleton
and multiple births are eligible for inclusion in this study and each infant will be provided with their own
unique study identification number. Infants will be included even if they were not identified during pregnancy
surveillance
Exclusion criteria is if the neonate is unable to feed on offering feeds, the mother does not intend to stay in
the study area for at least 6 months and women younger than 18 years old
Interventions Intervention includes vitamin A 50,000 International Units (IU) as retinol palmitate and minute amounts
of vitamin E in soybean oil, once orally within the first 3 days of life keeping a minimum period of 2 hours
between the birth and the dosing
Placebo capsule with minute amounts of vitamin E in soybean oil once orally within the first 3 days of life
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Outcomes Infant mortality assessed at 6 months of age, neonatal mortality (0-1 month) assessed at 1 month, incidence
of severe morbidity defined as hospitalizations due to any illness in the first 6 months of infancy, potential
adverse effects of vitamin A such as bulging fontanelle, vomiting, irritability, fever, diarrhoea, inability to suck
or feed, convulsions or any other condition that caused parents to be concerned, in the 3 days period following
administration of the supplement, and vitamin A and C reactive protein (CRP) status of a subsample of
infants at 2 weeks and 3 months of age
Starting date Anticipated date of first participant enrolment: July 1, 2010
Contact information Honorati Masanja
Ifakara Health Institute, PO Box 78373, Dar-es-Salaam,
Tanzania
Email: hmasanja@ihi.or.tz
Notes Target sample size: 32,000
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D A T A A N D A N A L Y S E S
Comparison 1. Neonatal vitamin A supplementation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause infant mortality at 6
months: risk ratios based on
cumulative risk (%, adjusted
for clustering)
5 Risk Ratio (Fixed, 95% CI) Subtotals only
1.1 Term infants 3 22721 Risk Ratio (Fixed, 95% CI) 0.82 [0.68, 0.99]
1.2 All infants 5 39040 Risk Ratio (Fixed, 95% CI) 0.86 [0.77, 0.97]
2 All-cause infant mortality at 6
months: rate ratios (per years of
follow-up)
4 Rate Ratio (Fixed, 95% CI) Subtotals only
2.1 Term infants 2 Rate Ratio (Fixed, 95% CI) 0.91 [0.73, 1.13]
2.2 All infants 4 Rate Ratio (Fixed, 95% CI) 0.91 [0.77, 1.06]
3 All-cause infant mortality at 12
months (all infants): risk ratios
based on cumulative risk (%)
4 15731 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.87, 1.20]
4 All-cause infant mortality at 12
months: rate ratios (per years of
follow-up)
4 Rate Ratio (Fixed, 95% CI) Subtotals only
4.1 Term infants 2 Rate Ratio (Fixed, 95% CI) 0.95 [0.72, 1.26]
4.2 All infants 4 Rate Ratio (Fixed, 95% CI) 1.03 [0.87, 1.23]
5 Cause-specific infant mortality at
6 months (all infants): Diarrhea
2 (Fixed, 95% CI) Totals not selected
5.1 Risk ratio 1 (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Rate ratio 1 (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Cause-specific infant mortality
at 6 months (all infants):
Respiratory infections
2 (Fixed, 95% CI) Totals not selected
6.1 Risk ratio 1 (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Rate ratio 1 (Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Cause-specific infant mortality
at 12 months (all infants):
Diarrhoea
3 (Fixed, 95% CI) Subtotals only
7.1 Risk ratios 1 (Fixed, 95% CI) 0.40 [0.08, 2.03]
7.2 Rate ratios 2 (Fixed, 95% CI) 1.32 [0.80, 2.16]
8 Cause-speciifc infant mortality
at 12 months (all infants):
Respiratory infections
3 (Fixed, 95% CI) Subtotals only
8.1 Risk ratios 1 (Fixed, 95% CI) 0.66 [0.11, 3.95]
8.2 Rate ratios 2 (Fixed, 95% CI) 0.97 [0.67, 1.42]
9 Infant morbidity at 6 months
(rate ratio): Diarrhoea
2 Rate ratio (Fixed, 95% CI) 1.05 [0.99, 1.10]
10 Infant morbidity at 6 months
(rate ratio): Respiratory
infections
2 Rate ratio (Fixed, 95% CI) 1.01 [0.96, 1.05]
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11 Vitamin A deficient (serum
retinol <0.70 micromol/L) at 6
weeks of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12 Vitamin A deficient (serum
retinol <0.70 micromol/L) at 4
months of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
13 Anaemia (haemoglobin
<105g/L) at 8-14 months of
age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
14 Adverse events during
the first 48-72 hours post
supplementation
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Bulging fontanelle 2 3158 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.04, 1.82]
14.2 Diarrhoea 2 3159 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.77, 1.09]
14.3 Vomiting 2 3159 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.74, 1.05]
15 Adverse events during the first
month post supplementation
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15.1 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 1 All-cause
infant mortality at 6 months: risk ratios based on cumulative risk (%, adjusted for clustering).
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 1 All-cause infant mortality at 6 months: risk ratios based on cumulative risk (%, adjusted for clustering)
Study or subgroup Favours vitamin A Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Term infants
Humphrey 1996 1011 1007 -0.9163 (0.4776) 4.2 % 0.40 [ 0.16, 1.02 ]
Klemm 2008 6109 6061 -0.2877 (0.1206) 65.5 % 0.75 [ 0.59, 0.95 ]
Malaba 2005 4253 4280 0.0862 (0.1773) 30.3 % 1.09 [ 0.77, 1.54 ]
Subtotal (95% CI) 11373 11348 100.0 % 0.82 [ 0.68, 0.99 ]
Heterogeneity: Chi2 = 5.38, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.06 (P = 0.040)
2 All infants
Humphrey 1996 1034 1033 -0.9416 (0.4861) 1.6 % 0.39 [ 0.15, 1.01 ]
Klemm 2008 7953 7984 -0.1586 (0.0845) 52.1 % 0.85 [ 0.72, 1.01 ]
Malaba 2005 4309 4352 0.1133 (0.1717) 12.6 % 1.12 [ 0.80, 1.57 ]
0.2 0.5 1 2 5
Favours vitamin A Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Favours vitamin A Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Rahmathullah 2003 5363 5408 -0.2485 (0.1171) 27.1 % 0.78 [ 0.62, 0.98 ]
West 1995 819 785 0.0677 (0.2361) 6.7 % 1.07 [ 0.67, 1.70 ]
Subtotal (95% CI) 19478 19562 100.0 % 0.86 [ 0.77, 0.97 ]
Heterogeneity: Chi2 = 6.57, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 2.39 (P = 0.017)
0.2 0.5 1 2 5
Favours vitamin A Favours control
Analysis 1.2. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 2 All-cause
infant mortality at 6 months: rate ratios (per years of follow-up).
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 2 All-cause infant mortality at 6 months: rate ratios (per years of follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Term infants
Benn 2008 0.131 (0.1948) 33.2 % 1.14 [ 0.78, 1.67 ]
Rahmathullah 2003 -0.2107 (0.1372) 66.8 % 0.81 [ 0.62, 1.06 ]
Subtotal (95% CI) 100.0 % 0.91 [ 0.73, 1.13 ]
Heterogeneity: Chi2 = 2.06, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.87 (P = 0.39)
2 All infants
Benn 2008 0.13102826 (0.19420535) 16.8 % 1.14 [ 0.78, 1.67 ]
Benn 2010 0.0099 (0.1796) 19.7 % 1.01 [ 0.71, 1.44 ]
Rahmathullah 2003 -0.25059 (0.110311) 52.1 % 0.78 [ 0.63, 0.97 ]
West 1995 0.067434 (0.236067) 11.4 % 1.07 [ 0.67, 1.70 ]
Subtotal (95% CI) 100.0 % 0.91 [ 0.77, 1.06 ]
Heterogeneity: Chi2 = 4.16, df = 3 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.24 (P = 0.21)
0.05 0.2 1 5 20
Favours vitamin A Favours control
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Analysis 1.3. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 3 All-cause
infant mortality at 12 months (all infants): risk ratios based on cumulative risk (%).
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 3 All-cause infant mortality at 12 months (all infants): risk ratios based on cumulative risk (%)
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Benn 2008 88/2106 86/2169 32.2 % 1.05 [ 0.79, 1.41 ]
Benn 2010 83/701 78/710 29.5 % 1.08 [ 0.81, 1.44 ]
Humphrey 1996 (1) 7/925 19/914 7.3 % 0.36 [ 0.15, 0.86 ]
Malaba 2005 88/4079 82/4127 31.0 % 1.09 [ 0.81, 1.46 ]
Total (95% CI) 7811 7920 100.0 % 1.02 [ 0.87, 1.20 ]
Total events: 266 (Vitamin A), 265 (Control)
Heterogeneity: Chi2 = 5.84, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin A Favours control
(1) Contains 6% preterms
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Analysis 1.4. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 4 All-cause
infant mortality at 12 months: rate ratios (per years of follow-up).
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 4 All-cause infant mortality at 12 months: rate ratios (per years of follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Term infants
Benn 2008 0.0677 (0.1516) 89.5 % 1.07 [ 0.79, 1.44 ]
Humphrey 1996 (1) -1.0216 (0.4421) 10.5 % 0.36 [ 0.15, 0.86 ]
Subtotal (95% CI) 100.0 % 0.95 [ 0.72, 1.26 ]
Heterogeneity: Chi2 = 5.43, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.33 (P = 0.74)
2 All infants
Benn 2008 0.0709 (0.1516) 33.2 % 1.07 [ 0.80, 1.44 ]
Benn 2010 0.0769 (0.1584) 30.4 % 1.08 [ 0.79, 1.47 ]
Humphrey 1996 -1.0216 (0.4421) 3.9 % 0.36 [ 0.15, 0.86 ]
Malaba 2005 0.0811 (0.153489) 32.4 % 1.08 [ 0.80, 1.47 ]
Subtotal (95% CI) 100.0 % 1.03 [ 0.87, 1.23 ]
Heterogeneity: Chi2 = 5.93, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.38 (P = 0.70)
0.01 0.1 1 10 100
Favours vitamin A Favours control
(1) Contains 6% preterms
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Analysis 1.5. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 5 Cause-specific
infant mortality at 6 months (all infants): Diarrhea.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 5 Cause-specific infant mortality at 6 months (all infants): Diarrhea
Study or subgroup log []
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Risk ratio
Humphrey 1996 -1.6094 (1.0858) 0.20 [ 0.02, 1.68 ]
2 Rate ratio
Rahmathullah 2003 -0.4005 (0.3727) 0.67 [ 0.32, 1.39 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
Analysis 1.6. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 6 Cause-specific
infant mortality at 6 months (all infants): Respiratory infections.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 6 Cause-specific infant mortality at 6 months (all infants): Respiratory infections
Study or subgroup log []
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Risk ratio
Humphrey 1996 -0.4155 (0.9076) 0.66 [ 0.11, 3.91 ]
2 Rate ratio
Rahmathullah 2003 0.0019 (0.2949) 1.00 [ 0.56, 1.79 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
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Analysis 1.7. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 7 Cause-specific
infant mortality at 12 months (all infants): Diarrhoea.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 7 Cause-specific infant mortality at 12 months (all infants): Diarrhoea
Study or subgroup log [] Weight
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Risk ratios
Humphrey 1996 -0.9163 (0.8287) 100.0 % 0.40 [ 0.08, 2.03 ]
Subtotal (95% CI) 100.0 % 0.40 [ 0.08, 2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 Rate ratios
Benn 2008 0.47 (0.3536) 50.8 % 1.60 [ 0.80, 3.20 ]
Malaba 2005 0.076 (0.3594) 49.2 % 1.08 [ 0.53, 2.18 ]
Subtotal (95% CI) 100.0 % 1.32 [ 0.80, 2.16 ]
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
0.01 0.1 1 10 100
Favours vitamin A Favours control
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Analysis 1.8. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 8 Cause-speciifc
infant mortality at 12 months (all infants): Respiratory infections.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 8 Cause-speciifc infant mortality at 12 months (all infants): Respiratory infections
Study or subgroup log [] Weight
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Risk ratios
Humphrey 1996 -0.4155 (0.9128) 100.0 % 0.66 [ 0.11, 3.95 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.11, 3.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 Rate ratios
Benn 2008 0.0953 (0.4188) 21.2 % 1.10 [ 0.48, 2.50 ]
Malaba 2005 -0.0596 (0.2171) 78.8 % 0.94 [ 0.62, 1.44 ]
Subtotal (95% CI) 100.0 % 0.97 [ 0.67, 1.42 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
0.01 0.1 1 10 100
Favours vitamin A Favours control
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Analysis 1.9. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 9 Infant
morbidity at 6 months (rate ratio): Diarrhoea.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 9 Infant morbidity at 6 months (rate ratio): Diarrhoea
Study or subgroup log [Rate ratio] Rate ratio Weight Rate ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Malaba 2005 0.0488 (0.0765) 12.3 % 1.05 [ 0.90, 1.22 ]
Rahmathullah 2003 0.0449 (0.0287) 87.7 % 1.05 [ 0.99, 1.11 ]
Total (95% CI) 100.0 % 1.05 [ 0.99, 1.10 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vitamin A Favours control
Analysis 1.10. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 10 Infant
morbidity at 6 months (rate ratio): Respiratory infections.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 10 Infant morbidity at 6 months (rate ratio): Respiratory infections
Study or subgroup log [Rate ratio] Rate ratio Weight Rate ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Malaba 2005 -0.0202 (0.0253) 80.7 % 0.98 [ 0.93, 1.03 ]
Rahmathullah 2003 0.1293 (0.0518) 19.3 % 1.14 [ 1.03, 1.26 ]
Total (95% CI) 100.0 % 1.01 [ 0.96, 1.05 ]
Heterogeneity: Chi2 = 6.73, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vitamin A Favours control
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Analysis 1.11. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 11 Vitamin A
deficient (serum retinol <0.70 micromol/L) at 6 weeks of age.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 11 Vitamin A deficient (serum retinol <0.70 micromol/L) at 6 weeks of age
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Benn 2008 91/292 106/320 0.94 [ 0.75, 1.19 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
Analysis 1.12. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 12 Vitamin A
deficient (serum retinol <0.70 micromol/L) at 4 months of age.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 12 Vitamin A deficient (serum retinol <0.70 micromol/L) at 4 months of age
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Benn 2008 30/186 29/183 1.02 [ 0.64, 1.62 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
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Analysis 1.13. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 13 Anaemia
(haemoglobin <105g/L) at 8-14 months of age.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 13 Anaemia (haemoglobin <105g/L) at 8-14 months of age
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Malaba 2005 (1) 368/809 369/783 0.97 [ 0.87, 1.07 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
(1) Includes both HIV +/ - mothers but HIV status of the m/i did not modify the association b/w vitamin A supplementation and anaemia
Analysis 1.14. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 14 Adverse
events during the first 48-72 hours post supplementation.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 14 Adverse events during the first 48-72 hours post supplementation
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bulging fontanelle
Benn 2008 60/551 56/599 68.2 % 1.16 [ 0.82, 1.65 ]
Humphrey 1996 46/1007 25/1001 31.8 % 1.83 [ 1.13, 2.95 ]
Subtotal (95% CI) 1558 1600 100.0 % 1.38 [ 1.04, 1.82 ]
Total events: 106 (Intervention), 81 (Control)
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 2.24 (P = 0.025)
2 Diarrhoea
Benn 2008 103/551 146/599 60.8 % 0.77 [ 0.61, 0.96 ]
Humphrey 1996 104/1008 90/1001 39.2 % 1.15 [ 0.88, 1.50 ]
Subtotal (95% CI) 1559 1600 100.0 % 0.92 [ 0.77, 1.09 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 207 (Intervention), 236 (Control)
Heterogeneity: Chi2 = 5.12, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 1.00 (P = 0.32)
3 Vomiting
Benn 2008 104/551 123/599 51.9 % 0.92 [ 0.73, 1.16 ]
Humphrey 1996 92/1008 109/1001 48.1 % 0.84 [ 0.64, 1.09 ]
Subtotal (95% CI) 1559 1600 100.0 % 0.88 [ 0.74, 1.05 ]
Total events: 196 (Intervention), 232 (Control)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
0.01 0.1 1 10 100
Favours vitamin A Favours control
Analysis 1.15. Comparison 1 Neonatal vitamin A supplementation versus control, Outcome 15 Adverse
events during the first month post supplementation.
Review: Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in developing countries
Comparison: 1 Neonatal vitamin A supplementation versus control
Outcome: 15 Adverse events during the first month post supplementation
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Diarrhoea
Benn 2008 11/991 10/964 1.07 [ 0.46, 2.51 ]
2 Vomiting
Benn 2008 15/991 12/964 1.22 [ 0.57, 2.58 ]
0.01 0.1 1 10 100
Favours vitamin A Favours control
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A D D I T I O N A L T A B L E S
Table 1. Data type and source: all-cause infant mortality at 6 months
Study ID Analyzed
as Rate/
Risk ratio
Data
source
(term/all
infants)
Infants Vitamin A
group:
Deaths
Vitamin A
group:
Child-
years of
follow-up
Vitamin A
group:
N
Control
group:
Deaths
Control
group:
Child-
years of
follow-up
Control
group:
N
Benn 2008 Rate ratio Corre-
spon-
dence with
study in-
vestigators
All infants 55 964 - 50 1003 -
Benn 2010 Rate ratio Corre-
spon-
dence with
study in-
vestigators
All infants 62 393 - 62 397 -
Humphrey
1996
Risk ratio Corre-
spondence
with study
investi-
gators (de-
nom-
inators are
number of
neonates
ran-
domised)
All infants 7 - 1034 18 - 1033
Term
infants
6 - 1011 15 - 1007
Klemm
2008
Risk ratio Klemm
at al, Pedi-
atrics
2008;122
(1):e242-
50.
All infants 306 - 7953 360 - 7984
Term
infants
129 - 6109 171 - 6061
Malaba
2005
Risk ratio Corre-
spondence
with study
investiga-
tors. Data
aggre-
gated for
the four
treatment
groups:
Maternal
All infants 73 - 4309 66 - 4352
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Table 1. Data type and source: all-cause infant mortality at 6 months (Continued)
vitamin A
and infant
vitamin A
+ maternal
placebo
and infant
vitamin
A versus
maternal
placebo
and infant
placebo +
maternal
vitamin A
and infant
placebo
(For term
infants,
denomi-
nators are
number
of HIV
negative
mothers
with term
deliveries)
Term
infants
62 - 4253 57 - 4280
Rahmath-
ullah
2003
Rate ratio/
Risk ratio
Rahmath-
ullah et al,
BMJ
2003;327
(7409):
254.
All infants 146 2713 5363 188 2719.1 5408
Corre-
spon-
dence with
study in-
vestigators
Term
infants
106 2348.7 - 130 2346.7 -
West 1995 Rate ratio/
Risk ratio
West et al,
American
Journal
of Clinical
Nutrition
1995;62
(1):143-8.
Data were
ex-
All infants 38 268.4 819 34 256.9 785
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Table 1. Data type and source: all-cause infant mortality at 6 months (Continued)
tracted for
infants un-
der 1
month old
who had
been al-
located to
treatment
Klemm 2008 was a cluster randomised study. The study authors reported that observed design effect was 0.9%.
West 1995 was a cluster randomised study. The study authors reported that the 95% confidence intervals of the effect estimates were
inflated by 10% to account for the impact of the design on the study. We estimated that the 10% increase in the 95% CIs gave an ICC
of 0.04 for the cohort of infants administered Vitamin A.
Table 2. Data type and source: all-cause infant mortality at 12 months
Study ID Analyzed
as Rate/
Risk ratio
Data
source
Infants Vitamin A
group:
Deaths
Vitamin A
group:
Child-
years of
follow-up
Vitamin A
group:
N
Control
group:
Deaths
Control
group:
Child-
years of
follow-up
Control
group:
N
Benn 2008 Rate ratio/
risk ratio
Benn et al,
BMJ
2008;336
(7658):
1416-20.
All infants 88 1795 2106 86 1884 2169
Benn 2010 Rate ratio/
risk ratio
Benn et al,
BMJ
2010;340:
c1101.
All infants 83 757 701 78 762 710
Humphrey
1996
Rate ratio/
risk ratio
Humphrey
et al, Jour-
nal of Pedi-
atrics
1996;128
(4):489-
96.
All
infants (in-
cludes 6%
preterms)
7 969.6 925 19 957.1 914
Klemm
2008
- - - - - - - - -
Malaba
2005
Rate ratio/
risk ratio
Malaba
et al, The
American
Journal of
All infants 88 4195 4079 82 4239 4127
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Table 2. Data type and source: all-cause infant mortality at 12 months (Continued)
Clinical
Nutrition
2005;81
(2):454-
60. Data
aggre-
gated for
the four
treatment
groups:
Maternal
vitamin A
and infant
vitamin A
+ maternal
placebo
and infant
vitamin
A versus
maternal
placebo
and infant
placebo +
maternal
vitamin A
and infant
placebo
Rahmath-
ullah
2003
- - - - - - - - -
West 1995 - - - - - - - - -
WH A T ’ S N E W
Last assessed as up-to-date: 30 November 2010.
Date Event Description
13 March 2012 Amended Minor typographical error corrected.
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H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 10, 2011
Date Event Description
14 May 2008 Amended Reference correction
8 May 2008 Amended Converted to new review format.
12 October 2007 New citation required and major changes Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
The review protocol was written by Batool A Haider (BAH) under the guidance of Zulfiqar A Bhutta (ZAB). Data extraction was done
by BAH and ZAB. BAH entered the data, created the comparisons, did data analysis and wrote the text of the review. ZAB provided
supervision and contributed to the writing process of the review.
D E C L A R A T I O N S O F I N T E R E S T
Zulfiqar A Bhutta is a principal investigator of an ongoing neonatal vitamin A supplementation trial in Pakistan.
S O U R C E S O F S U P P O R T
Internal sources
• The Aga Khan University Hospital, Pakistan.
External sources
• World Health Organization, Switzerland.
A grant was provided by the WHO to fund the completion of this Cochrane Review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Developing Countries; ∗InfantMortality; ∗Morbidity; Randomized ControlledTrials as Topic; Vitamin A [∗administration &dosage];
Vitamin A Deficiency [prevention & control]; Vitamins [∗administration & dosage]
MeSH check words
Humans; Infant, Newborn
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